Chief Commercial Officer · IDEAYA Biosciences, Inc. (IDYA)

Stuart Dorman

FY2024 is the first fiscal year CompBrief holds for Stuart Dorman as a named executive officer of IDEAYA Biosciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,420,258

Salary $41,667Stock awards $0Bonus $100,000

5th of 6 named executive officers at Ideaya Biosciences by FY2024 total.

6 named officers on file for IDEAYA Biosciences, FY2024

Stuart Dorman’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • IDYA’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how IDEAYA Biosciences’s whole pay program stands against its peers

  • IDEAYA Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IDYA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Stuart Dorman’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Stuart Dorman compensation by year

IDEAYA Biosciences Summary Compensation Table · the one fiscal year held
In US dollars, as IDEAYA Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$41,667
Bonus$100,000
Stock awards$0
Option awards$3,258,441
Non-equity incentive$20,000
Pension and deferred compensation$0
All other$150
Total$3,420,258

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IDEAYA Biosciences, Inc. DEF 14A filed April 30, 2025, accession 0000950170-25-060530, and prior-year filings. Open the filing on EDGAR.

How this page was built: the IDEAYA Biosciences, Inc. filed document, accession 0000950170-25-060530. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option170,000—$27.45

Per the Outstanding Equity Awards at Fiscal Year-End table in IDEAYA Biosciences, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2024 proxy (filed April 30, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-30Grant or award derivative—155,000$0.00155,000

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

IDEAYA Biosciences’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Yujiro HataPresident and Chief Executive Officer$16,930,872
Darrin BeaupreChief Medical Officer$6,060,624
Michael WhiteChief Scientific Officer$5,379,396
Jason ThroneFormer Chief Legal Officer$4,470,270
Stuart Dorman · this pageChief Commercial Officer$3,420,258
Andres Ruiz BrisenoChief Accounting Officer$3,355,794

The full IDEAYA Biosciences compensation record

free company brief

This page is one person within IDEAYA Biosciences's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the IDEAYA Biosciences proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IDEAYA Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Stuart Dorman's compensation dossier · One-time report. No refunds.